CI
CLDI icon

CPR Investments’s Calidi Biotherapeutics CLDI Stock Holding History

CPR Investments’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-526
Closed -$23.2K – 52
2025
Q2 		$23.2K Hold
526
– – 0.02% 45
2025
Q1 		$57.2K Hold
526
– – 0.05% 37
2024
Q4 		$116K Buy
526
+234
+80% +$70.2K 0.1% 35
2024
Q3 		$63.8K Hold
292
– – 0.06% 37
2024
Q2 		$112K Buy
292
+256
+711% +$131K 0.09% 42
2024
Q1 		$44.8K Buy
+36
New +$58.8K 0.03% 48

Other funds holding CLDI

HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
BAM
Belpointe Asset Management Reno, Nevada $3.06B AUM 23.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $551M AUM 34.68% 1-Year Est. Return
RCI
RS Crum Inc Newport Beach, California $533M AUM 20.75% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $2.8B AUM 13.35% 1-Year Est. Return
AMH
Apollo Management Holdings New York $8.94B AUM 120.19% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return

CPR Investments's CLDI Position: Q3 2025 in Review

CPR Investments sold out of Calidi Biotherapeutics (CLDI) in Q3 2025, closing a stake of 526 shares — an estimated $23.2K sold.

CPR Investments first reported a position in CLDI in Q1 2024 and held it in 6 quarters. The position peaked at $116K in Q4 2024. 21 funds tracked by Wall St. Rank hold CLDI as of Q3 2025.

  • CPR Investments reported no remaining Calidi Biotherapeutics position as of Q3 2025 after selling out during the quarter.
  • CPR Investments sold 526 Calidi Biotherapeutics shares in Q3 2025, an estimated $23.2K.
  • CPR Investments first reported a position in Calidi Biotherapeutics in Q1 2024 and held it in 6 quarters.
  • CPR Investments's Calidi Biotherapeutics position peaked at $116K in Q4 2024.
  • 21 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q3 2025.

Based on CPR Investments's 13F filing for Q3 2025, filed 14 Oct 2025.